Companies Cryptocurrencies
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Exchange: Nasdaq Global Select
IPO Date: 31/01/2014
CEO: Dr. Sharon Mates
Biotechnology Healthcare 🔗
  • ITCI
    symbol
  • price
  • market cap
  • changes
If you bought

shares of Intra-Cellular Therapies Inc (ITCI) on
You would have made
AMOUNT
today.
Old Price $12 Current Price $12

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The company is headquartered in New York City, New York and currently employs 73 full-time employees. The firm is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The firm is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The firm’s bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The firm initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer’s Disease (AD).

Address: 430 E 29th St New York City NEW YORK 10016

Stay updated.